Healthcare & Life Sciences Insights

Discover Latham’s latest insights into the commercial, regulatory, and legal developments shaping the global healthcare and life sciences landscape.

Latham’s cross-disciplinary team delivers insightful, practical guidance and sophisticated representation to a full spectrum of healthcare and life sciences companies across the globe, on every type of transaction or dispute a company may face.

Learn more about our capabilities

Pipetting a DNA (deoxyribonucleic acid) sample into a multiwell plate with DNA information in the background

In the Spotlight

Healthcare & Life Sciences Market Update

Shiny transparent capsule filled with colorful spheres

March 12, 2025 Podcast

Episode 95 — Drug Pricing: FDA in the Age of Executive Orders and DOGE

March 5, 2025 Blog

HHS Issues Policy Statement to Expand Use of Rulemaking Without Notice and Comment

February 25, 2025 Podcast

Episode 94 — Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook

October 18, 2024 Client Alert

US State Regulatory Spotlight on Healthcare Transactions: Reflections From 2024

Riyadh skyline at night #7, Capital of Saudi Arabia

March 19, 2025 Client Alert

Saudi Arabia Issues Decree to Permit Foreign Ownership of Retail Pharmacies

The new law, which offers a unique opportunity for investors in Saudi Arabia’s pharmacy market, forms part of a broader strategy to encourage innovation and foreign investment.

The White House of the United States of America Building

March 14, 2025 Blog

Week 8 in Review: Legal Challenges Abound Amid Continued Rollbacks

The Trump administration continues to rollback policies on DEI and banking regulation while facing various lawsuits over its personnel, spending, and immigration actions.

March 12, 2025 Podcast

Episode 95 — Drug Pricing: FDA in the Age of Executive Orders and DOGE

March 12, 2025 Article

Takeaways From Biotech IPOs So Far in 2025

March 11, 2025 Client Alert

First Circuit Reins In Broad Theory of Liability Under Anti-Kickback Statute by Adopting “But-For Causation” Standard

March 12, 2025

Episode 95 — Drug Pricing: FDA in the Age of Executive Orders and DOGE

The Department of Government Efficiency, Trump executive orders, and a recent Office of Management and Budget memorandum are making drastic changes at FDA. The Latham team discusses the potential impacts on FDA approval and enforcement activities, including with respect to novel tobacco and nicotine products.

February 25, 2025

Episode 94 — Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook

One of the country’s largest healthcare conferences recently concluded in San Francisco. Join the Latham team to discuss takeaways from the conference, including AI innovation and increased dealmaking activity, and consider the policy outlook under the new Trump administration.

Drop of clear blue liquid from droper droping to test tube in laboratory with bright color blur background.

December 30, 2024

Episode 89 — The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech — Then, Now, and What’s Next?

Latham speaks with BridgeBio’s CEO/founder and CFO about BBIO’s growth story — its past, present, and future.

December 17, 2024

Episode 88 — Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?

Explore recent FDA enforcement trends and the agency’s current focus, and consider potential priorities under the incoming Trump Administration.

November 26, 2024

Episode 87 — Drug Pricing: What’s in the New CMS Medicaid Final Rule?

CMS sought far-reaching changes to the Medicaid Drug Rebate Program in its 2023 proposed rule implementing the Medicaid Services Investment and Accountability Act. Find out which proposals CMS dropped from the final rule, and which changes became effective November 19, 2024.

October 21, 2024

Episode 86 — Drug Pricing: Takeaways From the Chicago Medicaid Drug Rebate Program Summit

One of the year’s major drug pricing conferences just concluded in Chicago. Join the Latham team to discuss takeaways from the conference, including highlights from remarks by government speakers.

Front View of US Supreme Court in Washington DC, including the inscription Equal Justine Under Law

September 19, 2024

The Demise of Chevron Deference and Its Impact on the Healthcare and Life Sciences Industries

Latham lawyers discuss the implications of the US Supreme Court decision in Loper Bright. MCLE credit offered.

September 19, 2024

Episode 85 — Drug Pricing: How the Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

Recent Supreme Court decisions, such as those overruling Chevron deference, as well as ongoing manufacturer challenges to the Inflation Reduction Act and state 340B laws, will likely have a significant impact on the pharmaceutical industry.

August 19, 2024

Episode 83 — Drug Pricing: How Are Payers Responding to the IRA?

Explore how health insurance companies are adapting to the Inflation Reduction Act's new requirements, including the Part D redesign.

June 21, 2024

Episode 82 — Drug Pricing: Takeaways From the New Orleans Pricing and Contracting USA Conference

One of the year’s major drug pricing conferences just concluded in New Orleans. Join the Latham team to discuss takeaways from the conference, with topics including 340B developments, state legislative activity, and IRA implementation.

June 13, 2024

Episode 81 — Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals

The new ASP reporting website highlights the increasing significance of data collection portals — and yet the number of permitted users is very small. Join us as we learn from leading practitioners at Riparian how to navigate the complex web of compliance requirements.